Prestige Brands stock price target lowered to $100 at Canaccord on eye care supply issues

Prestige Brands (PBH) reported Q1 FY26 sales of $249.5 million, down 6.6% year-over-year, and adjusted EPS of $0.95, both missing estimates primarily due to Clear Eyes supply constraints, leading to a stock decline and revised fiscal 2026 guidance. Despite these operational challenges, the company maintains robust liquidity with a 4.2x current ratio and projects solid EBITDA margins and free cash flow of at least $245 million. Canaccord Genuity, while lowering its price target to $100, reiterated a Buy rating, deeming the stock an "excellent opportunity" at 14.6 times next year's earnings, citing its high-quality, high-margin, staple-like nature and strong free cash flow compared to higher-valued large-cap peers. Separately, PBH initiated a voluntary recall of specific Little Remedies Honey Cough Syrup lots due to contamination.

Analysis

Prestige Brands (PBH) reported a challenging first quarter for fiscal 2026, with revenue declining 6.6% year-over-year to $249.5 million and adjusted EPS at $0.95, missing both management's guidance and analyst estimates. The underperformance was primarily driven by specific operational headwinds, namely Clear Eyes supply constraints, which caused an 8.4% drop in North American sales and led management to lower its full-year guidance. This news, compounded by a voluntary recall of its Little Remedies Honey Cough Syrup due to contamination, contributed to an 8% decline in the stock price over the past week. Despite these near-term setbacks, the company's underlying financial health appears robust, evidenced by a 4.2x current ratio, projected EBITDA margins in the low-to-mid 30% range, and expected free cash flow of at least $245 million. This financial stability creates a valuation argument, with Canaccord Genuity highlighting the stock now trades at 14.6 times forward earnings—a significant discount to large-cap peers in the mid-20x range—leading the firm to reiterate a Buy rating and label the dip an "excellent opportunity." Jefferies, however, maintains a more cautious Hold rating, reflecting the current operational uncertainty.

Key Decisions for Investors

• Value-oriented investors could consider the recent share price weakness a strategic entry point, given the stock's valuation discount to peers at 14.6x forward earnings, provided the Clear Eyes supply issue is viewed as a temporary disruption.
• Investors should closely monitor management's progress in resolving the eye care supply constraints, as this is the key determinant for the company meeting its revised fiscal 2026 guidance.
• Given the conflicting analyst ratings and the contrast between near-term operational issues and strong underlying free cash flow, a hold strategy may be prudent until there is clearer evidence of operational stabilization in the coming quarters.